Navigation Links
Patent Office Rules in Neuralstem's Favor in Dispute with StemCells, Inc.
Date:9/19/2007

ROCKVILLE, Md., Sept. 19 /PRNewswire-FirstCall/ -- Stem cell company, Neuralstem, Inc. (AMEX: CUR), announced today that it has received notice that the United States Patent and Trademark Office (USPTO) has issued its first ruling in the reexamination of the four StemCells, Inc. (Nasdaq: STEM) patents requested by Neuralstem.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

"The Patent Office has rejected on multiple grounds all of the claims in all four of StemCells' patents that it examined," said Neuralstem President & CEO, Richard Garr. "In accepting the reexamination months ago," Garr explained, "the Patent Office was only ruling that, on its face, there was enough evidence to disallow the claims. Now after careful examination, the Patent Office has issued an official rejection of each of the claims in all four of the patents that StemCells attempted to assert against Neuralstem in its law suit. Importantly the Patent Office is rejecting the StemCells patents based on additional prior art references that were not even the focus of our reexamination request. We are pleased but certainly not surprised by the Patent Office's rejection of all the claims in all the relevant StemCells patents," Garr went on to say. "We believe that the Patent Office has now correctly found that these claims should never have been issued in the first place."

About Neuralstem

Neuralstem's patent-protected technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into matu
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Changes to U.S. patent law must nurture our culture of innovation
2. WARF questions relevancy of documents used to uphold patent challenge
3. Supreme Court limits foreign reach of U.S. patents
4. High court sends message on patent obviousness
5. Supreme Court ruling seen as blow to WARF stem cell patents
6. Patent licensing: For enforcing companies, the rules have changed
7. Patent ruling doesnt tarnish Wisconsins stem cell leadership
8. Heres why Wisconsins stem cell patents are being challenged
9. WARF is likely to hold on to stem cell patent rights
10. Patent office upholds challenge to WARF stem cell patents
11. Rocket docket speeds patent infringement suits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
(Date:12/2/2009)QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today annou
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...e and Introduces Q1 2008 Guidance, FRAZER, Pa., F...ed 2007 sales of $1.727 billion, compared to sales...,s previously issued,guidance. Basic loss per comm...ng the previously announced settlement reserve, am...adjusted income per common share for the,full year...
... Technology Leadership, INDIANAPOLIS, Feb. 12 Th...wholly owned subsidiary of The Dow Chemical,Compan...ade to investors,earlier today by Jerome Peribere,...as speaking at the Goldman Sachs Agricultural Chem...rced Dow AgroSciences,technology-based strategy of...
...Corporation (NYSE: CBM ) announced that it will r... results on Thursday, February 14, 2008 after,mark.../prnh/20000613/CAMBREXLOGO ), The Company will h...r,and full year 2007 financial results., ...s Conference Call, When: Friday, Februa...
Other Biology Technology:Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 2Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 3Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 4Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 5Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 6Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 7Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 8Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 9Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 10Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 11Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 12Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 13Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 14Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 15Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 16Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 17Dow AgroSciences' Success Presented to Wall Street 2
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
(Date:12/3/2009)Spanish researchers have measured CO2 levels for the past three years in the troposphere (lower atmosphere) over a sparsely inhabited rural area near Valladolid. The results, which are the first of th
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
Breaking Biology News(10 mins):CO2 levels rising in troposphere over rural areas 2Grooving down the helix 2Grooving down the helix 3Power Plate 28R 29 Opens Cutting Edge Studio in L A 49383 1Power Plate 28R 29 Opens Cutting Edge Studio in L A 49383 2Benefit of glinides is not proven 49380 1Benefit of glinides is not proven 49380 2Benefit of glinides is not proven 49380 37th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 17th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 27th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 3
...e investigating exactly how chemotherapy drugs kil...s and test the effectiveness of safer new agents. ...versity of Manchester,s Faculty of Life Sciences h...ti-mitotic drugs, which are used extensively for b...f drugs, which includes the agent taxol, has been ...
...imate change, researchers at BBSRC-supported Rotha...amaging aphids the peach-potato aphid (Myzus pers...er for every 1C rise in mean temperature for Janua...hid was caught on 25 April, which is almost four w...eported in BBSRC Business, the quarterly researc...
...erated in health care, computational biology, home... massive and unstructured data sets has proven cum...known as data and visual analytics is helping sift... put together individual pieces of a picture. , T...five-year grant to lead and coordinate a new initi...
Other Biology News:How chemo kills tumors: research to reduce side effects 2How chemo kills tumors: research to reduce side effects 3Aphids are sentinels of climate change 2Grant supports emerging field of massive data analysis and visual analytics 2Grant supports emerging field of massive data analysis and visual analytics 3Grant supports emerging field of massive data analysis and visual analytics 4
Mouse Anti-Yersinia pestis F1 antigen Monoclonal Antibody, Unconjugated, Clone 1.F.1 from Abcam
Rabbit Anti-L Kynurenine Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-P5 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Drosophila Melanogaster Achaete protein Monoclonal Antibody, Unconjugated from Developmental Studies Hybridoma Bank
Biology Products: